A Bimetallic Metal–Organic‐Framework‐Based Biomimetic Nanoplatform Enhances Anti‐Leukemia Immunity via Synchronizing DNA Demethylation and RNA Hypermethylation
The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Epigenetic‐alterations‐mediated antigenicity reducing in leukemic blasts (LBs) is one of the critical mechanisms of immune escape and resistance to T‐cell‐based immunotherapy. Herein, a bimetallic metal–organic framework (MOF)‐based biomimetic nanoplatform (termed as AFMMB) that consists of a DNA hypomethylating agent, a leukemia stem cell (LSC) membrane, and pro‐autophagic peptide is fabricated. These AFMMB particles selectively target not only LBs but also LSCs due to the homing effect and immune compatibility of the LSC membrane, and induce autophagy by binding to the Golgi‐apparatus‐associated protein. The autophagy‐triggered dissolution of AFMMB releases active components, resulting in the restoration of the stimulator of interferon genes pathway by inhibiting DNA methylation, upregulation of major histocompatibility complex class‐I molecules, and induction of RNA‐methylation‐mediated decay of programmed cell death protein ligand transcripts. These dual epigenetic changes eventually enhance T‐cell‐mediated immune response due to increased antigenicity of leukemic cells. AFMMB also can suppress growth and metastases of solid tumor, which was suggestive of a pan‐cancer effect. These findings demonstrate that AFMMB may serve as a promising new nanoplatform for dual epigenetic therapy against cancer and warrants clinical validation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Dynamic RNA Modifications in Gene Expression Regulation
Roundtree, I. A., Evans, M. E., Pan, T., & He, C. (2017) · Cell · doi:10.1016/j.cell.2017.05.045 · Cited by 3,399
RNA modifications modulate gene expression during development
Frye, M., Harada, B. T., Behm, M., & He, C. (2018) · Science · doi:10.1126/science.aau1646 · Cited by 1,249
From Mechanism to Mouse: A Tale of Two Bioorthogonal Reactions
Sletten, E. M., & Bertozzi, C. R. (2011) · Accounts of Chemical Research · doi:10.1021/ar200148z · Cited by 1,093
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
Welch, J. S., Petti, A. A., Miller, C. A., Fronick, C. C., O’Laughlin, M., Fulton, R. S., Wilson, R. K., Baty, J. D., Duncavage, E. J., Tandon, B., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1605949 · Cited by 796
Sun, X., Zhang, Y., Li, J., Park, K. S., Han, K., Zhou, X., Xu, Y., Nam, J., Xu, J., Shi, X., et al. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00962-9 · Cited by 788
Short, N. J., Rytting, M. E., & Cortes, J. E. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31041-9 · Cited by 781
Pollyea, D. A., Stevens, B. M., Jones, C. L., Winters, A., Pei, S., Minhajuddin, M., D’Alessandro, A., Culp-Hill, R., Riemondy, K. A., Gillen, A. E., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0233-1 · Cited by 778
Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion
Su, R., Dong, L., Li, Y., Gao, M., Han, L., Wunderlich, M., Deng, X., Li, H., Huang, Y., Gao, L., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.04.017 · Cited by 763
Identification of a candidate therapeutic autophagy-inducing peptide
Shoji-Kawata, S., Sumpter, R., Leveno, M., Campbell, G. R., Zou, Z., Kinch, L., Wilkins, A. D., Sun, Q., Pallauf, K., MacDuff, D., et al. (2013) · Nature · doi:10.1038/nature11866 · Cited by 760
m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade
Yang, S., Wei, J., Cui, Y.-H., Park, G., Shah, P., Deng, Y., Aplin, A. E., Lu, Z., Hwang, S., He, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10669-0 · Cited by 743
Cancer‐Cell‐Biomimetic Nanoparticles for Targeted Therapy of Homotypic Tumors
Sun, H., Su, J., Meng, Q., Yin, Q., Chen, L., Gu, W., Zhang, P., Zhang, Z., Yu, H., Wang, S., et al. (2016) · Advanced Materials · doi:10.1002/adma.201602173 · Cited by 640
Porphyrin‐Based Metal–Organic Frameworks for Biomedical Applications
Chen, J., Zhu, Y., & Kaskel, S. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.201909880 · Cited by 597
Inorganic nanomaterials with rapid clearance for biomedical applications
Wang, X., Zhong, X., Li, J., Liu, Z., & Cheng, L. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00461h · Cited by 509
Clinical epigenetics: seizing opportunities for translation
Berdasco, M., & Esteller, M. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-018-0074-2 · Cited by 498
Zhu, J.-Y., Zheng, D.-W., Zhang, M.-K., Yu, W.-Y., Qiu, W.-X., Hu, J.-J., Feng, J., & Zhang, X.-Z. (2016) · Nano Letters · doi:10.1021/acs.nanolett.6b02786 · Cited by 498
Combining epigenetic drugs with other therapies for solid tumours — past lessons and future promise
Morel, D., Jeffery, D., Aspeslagh, S., Almouzni, G., & Postel-Vinay, S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0267-4 · Cited by 445
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission
Wei, A. H., Döhner, H., Pocock, C., Montesinos, P., Afanasyev, B., Dombret, H., Ravandi, F., Sayar, H., Jang, J.-H., Porkka, K., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004444 · Cited by 445
Engineered Extracellular Vesicles for Cancer Therapy
Zhang, X., Zhang, H., Gu, J., Zhang, J., Shi, H., Qian, H., Wang, D., Xu, W., Pan, J., & Santos, H. A. (2021) · Advanced Materials · doi:10.1002/adma.202005709 · Cited by 428
PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model
Zhang, L., Gajewski, T. F., & Kline, J. (2009) · Blood · doi:10.1182/blood-2009-03-206672 · Cited by 411
Self-citationAdvances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges
Short, N. J., Konopleva, M., Kadia, T. M., Borthakur, G., Ravandi, F., DiNardo, C. D., & Daver, N. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1011 · Cited by 368
Immune escape and immunotherapy of acute myeloid leukemia
Vago, L., & Gojo, I. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129204 · Cited by 341
Marked for death: Targeting epigenetic changes in cancer
Pfister, S. X., & Ashworth, A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.256 · Cited by 288
Yan, F., Al-Kali, A., Zhang, Z., Liu, J., Pang, J., Zhao, N., He, C., Litzow, M. R., & Liu, S. (2018) · Cell Research · doi:10.1038/s41422-018-0097-4 · Cited by 235
Self-citationAntitumor Agents Based on Metal–Organic Frameworks
Gao, P., Chen, Y., Pan, W., Li, N., Liu, Z., & Tang, B. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202102574 · Cited by 224
Recent Advances in Engineered Materials for Immunotherapy‐Involved Combination Cancer Therapy
Liang, J., Luo, G., Chen, W., & Zhang, X. (2021) · Advanced Materials · doi:10.1002/adma.202007630 · Cited by 203
Falahat, R., Berglund, A., Putney, R. M., Perez-Villarroel, P., Aoyama, S., Pilon-Thomas, S., Barber, G. N., & Mulé, J. J. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2013598118 · Cited by 190
Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis
Yamashita, M., Dellorusso, P. V., Olson, O. C., & Passegué, E. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0260-3 · Cited by 179
STING Pathway Activation Stimulates Potent Immunity against Acute Myeloid Leukemia
Curran, E., Chen, X., Corrales, L., Kline, D. E., Dubensky, T. W., Duttagupta, P., Kortylewski, M., & Kline, J. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.023 · Cited by 170
Epigenetic Remodeling in Innate Immunity and Inflammation
Zhang, Q., & Cao, X. (2021) · Annual Review of Immunology · doi:10.1146/annurev-immunol-093019-123619 · Cited by 156
Kadia, T. M., Reville, P. K., Wang, X., Rausch, C. R., Borthakur, G. M., Pemmaraju, N., Daver, N. G., Dinardo, C. D., Sasaki, K., Issa, G. C., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02823 · Cited by 132
Ehx, G., Larouche, J.-D., Durette, C., Laverdure, J.-P., Hesnard, L., Vincent, K., Hardy, M.-P., Thériault, C., Rulleau, C., Lanoix, J., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.03.001 · Cited by 122
From Design to Clinic: Engineered Nanobiomaterials for Immune Normalization Therapy of Cancer
Saeed, M., Chen, F., Ye, J., Shi, Y., Lammers, T., Geest, B. G. D., Xu, Z. P., & Yu, H. (2021) · Advanced Materials · doi:10.1002/adma.202008094 · Cited by 108
Targeting epigenetic pathway with gold nanoparticles for acute myeloid leukemia therapy
Deng, R., Shen, N., Yang, Y., Yu, H., Xu, S., Yang, Y.-W., Liu, S., Meguellati, K., & Yan, F. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.03.013 · Cited by 106
Self-citationYan, F., Shen, N., Pang, J. X., Zhang, Y. W., Rao, E. Y., Bode, A. M., Al-Kali, A., Zhang, D. E., Litzow, M. R., Li, B., et al. (2017) · Leukemia · doi:10.1038/leu.2016.349 · Cited by 102
Self-citationRNA N6-methyladenosine demethylase FTO regulates PD-L1 expression in colon cancer cells
Tsuruta, N., Tsuchihashi, K., Ohmura, H., Yamaguchi, T., Ito, M., Ariyama, H., Kusaba, H., Akashi, K., & Baba, E. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.06.153 · Cited by 102
New strategies to treat AML: novel insights into AML survival pathways and combination therapies
Nair, R., Salinas-Illarena, A., & Baldauf, H. (2020) · Leukemia · doi:10.1038/s41375-020-01069-1 · Cited by 93
Cao, K., Du, Y., Bao, X., Han, M., Su, R. J., Pang, J., Liu, S., Shi, Z., Yan, F., & Feng, S. (2022) · Small · doi:10.1002/smll.202106558 · Cited by 92
Self-citationDu, Y., Han, M., Cao, K., Li, Q., Pang, J., Dou, L., Liu, S., Shi, Z., Yan, F., & Feng, S. (2021) · ACS Nano · doi:10.1021/acsnano.1c05547 · Cited by 67
Self-citationYan, F., Shen, N., Pang, J. X., Zhao, N., Zhang, Y. W., Bode, A. M., Al‐Kali, A., Litzow, M. R., Li, B., & Liu, S. (2017) · Leukemia · doi:10.1038/leu.2017.307 · Cited by 60
Self-citationLiu, J., Song, Y., Wang, Y., Han, M., Wang, C., & Yan, F. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c09978 · Cited by 44
Self-citationOn behalf of the Acute Leukemia Working Party (ALWP) and Cellular Therapy and Immunobiology Working Party (CTIWP) of the European Society for Blood and Marrow Transplantation (EBMT), Lorentino, F., Labopin, M., Ciceri, F., Vago, L., Fleischhauer, K., Afanasyev, B. V., Kröger, N. M., Cornelissen, J. J., Lovira, M., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0863-4 · Cited by 37
Zhang, L., Song, Y., Cao, K., Du, Y., Han, M., Shi, Z., Yan, F., & Feng, S. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202107195 · Cited by 36
Self-citationDu, Y., Dai, X., Han, M., Wang, Z., Wang, Y., Shi, Z., Yan, F., & Feng, S. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.139635 · Cited by 18
Self-citation
Cited by
Quasi Fe MIL-53 nanozyme inducing ferroptosis and immunogenic cell death for cancer immunotherapy
Yan, Z., Bai, Y., Zhang, S., Kong, L., Wang, Y., Sun, H., Li, Y., Qiu, L., Zhang, R., Jiang, P., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57542-x · Cited by 117
“Notably,thespleenofthemice treated with Q-MIL-53(Fe) was smaller compared to the other groups, indicating reduced immune suppression and promoting antitumor immunity 87,88 (Supplementary Fig.”
Self-citationLi, B., Ashrafizadeh, M., & Jiao, T. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.129391 · Cited by 98
Mao, Z., Wang, B., Zhang, T., & Cui, B. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06265-2 · Cited by 55
Nanotherapeutics targeting autophagy regulation for improved cancer therapy
Liu, Y., Wang, Y., Zhang, J., Peng, Q., Wang, X., Xiao, X., & Shi, K. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.03.019 · Cited by 48
Self-citationYang, Y., Wang, N., Wang, Z., Yan, F., Shi, Z., & Feng, S. (2025) · ACS Nano · doi:10.1021/acsnano.4c12304 · Cited by 48
Self-citation
Metadata
- Authors
- Song, Y., Zhang, L., Wang, Y., Han, M., Wang, Z., Wang, N., Shao, B., Li, R., Cao, K., Song, M., Du, Y., & Yan, F.
- Affiliations
- Jilin University (CN)
- Corresponding author
- Yan, Fei
- ORCID
- Venue
- Advanced Materials
- Publisher
- Wiley
- Published
- 2023-03-12
- Volume
- 35
- Issue
- 16
- Pages
- e2210895-e2210895
- ISSN
- 0935-9648 (ISSN-L)
- 1521-4095
- OpenAlex
- W4319657107
- Cited by
- 54
- References
- 43
- Citations by year
- 2026: 12 · 2025: 19 · 2024: 19 · 2023: 4
- FWCI
- 4.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Advanced Materials (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (82170154, 81870117)
- Topics
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- bimetallic metal-organic frameworks, biomimetic nanoplatform, leukemia, DNA demethylation, RNA methylation, leukemia stem cells, autophagy, Golgi-associated proteins, T cell immunity, immune evasion, epigenetic therapy, MHC class I, antigenicity, nanomedicine
- MeSH terms
- Metal-Organic Frameworks, DNA Demethylation, Humans, RNA, Leukemia, Myeloid, Acute, DNA Methylation, Biomimetics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.